Haematologic Malignancies
Excellthera Inc. focuses on acute leukemia and myelodysplasia in patients with high-risk and very high-risk disease profiles, with particular attention to cases requiring allogeneic haematopoietic stem cell transplantation.
- High-risk acute leukemia
- Very high-risk acute leukemia
- Myelodysplasia
The therapeutic interest is centered on transplant-supported treatment pathways for advanced blood cancers.
Cord Blood Transplantation
The sponsor’s research activity includes cord blood transplantation, with emphasis on expanded cord blood use in the setting of difficult-to-treat haematological disease.
- Expanded cord blood grafts
- Transplant engraftment
- Graft failure risk
This area reflects a clinical interest in improving transplant availability and post-transplant outcomes for patients with limited donor options.
Transplant Safety and Feasibility
Clinical research activity is directed toward the safety and feasibility of expanded umbilical cord blood infusions in the transplant setting, with attention to graft performance and early transplant tolerance.
- Graft failure
- Infusion-related safety
- Transplant feasibility
The sponsor’s interest lies in transplant-compatible approaches for patients with aggressive marrow disease.
Post-Transplant Disease Control
Another key area is relapse-free survival after transplantation, reflecting a focus on maintaining disease remission in patients treated for advanced blood cancers.
- Relapse prevention
- Long-term transplant outcomes
- Remission maintenance
This domain links transplant strategy with durable control of high-risk malignant disease.
